Press

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Jan 12 • 5 min read

Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH | OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a U.S.-based joint venture named Magdalena Biosciences, Inc. to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. Initial funding of US$1,000,000 will be invested by Boulder, Colorado-based One Small Planet, founded…

Cybin Inc. Selects Generalized Anxiety Disorder as Target Indication for CYB004

Jan 12 • 2 min read

Cybin (NYSE American: CYBN | NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has…

Field Trip Health & Wellness Ltd. Announces Launch of Online Therapy

Jan 12 • 3 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW), a global leader in the delivery of psychedelic therapies, today launched Field Trip Online Therapy, a unique approach to psychotherapy that leverages contemporary talk therapy, integrative wellness tools and insights derived from being one of the largest global providers of psychedelic-assisted therapies. The new offering marks a…

Revive Therapeutics Ltd. Closes $4.3 Million Offering

Jan 12 • 2 min read

REVIVE THERAPEUTICS LTD. (CSE: RVV OTCQB: RVVTF | FRANKFURT:31R) is pleased to announce that it has completed the closing of its previously announced private placement by issuing a total of 28,676,064 units, at a price of $0.15 per Unit, for gross proceeds of $4,301,409. Each Unit is comprised of one common share in the capital…

Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US

Jan 10 • 4 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X), is proud to announce it has signed a Letter of Intent entering into a partnership with Braxia Scientific Corp. (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, to launch Clinical…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441